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Abstract:
Objective: The curative treatment approach for diffuse large B-cell lymphoma (DLBCL) is controversial even in the rituximab 
(R) era. The aim of this study was to examine the FcγRIIIA gene polymorphism distribution of DLBCL patients who had 
been treated with R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Furthermore, we 
investigated the impact of FcγRIIIA gene polymorphism on the overall response rate (ORR) and overall survival (OS).
Materials and Methods: Patients from 3 centers in the Aegean region of Turkey who had newly diagnosed CD20-positive 
DLBCL were enrolled in the study. The single nucleotide polymorphisms of the FcγRIIIA gene were analyzed by real time-
PCR. The response to treatment was determined in the middle and at the end of the protocol. During 2 years of follow-up, the 
patients were clinically and radiologically evaluated for disease status every 3 months.
Results: Thirty-six patients were included in the study and the distributions of F/F, V/F, and V/V types of alleles of FcγRIIIA 
were 25%, 50%, and 25%, respectively. Twenty-seven patients were considered as evaluable according to ORR and OS. The 
patients’ oRR was 87.5%, 100%, and 50% in the F/F, V/F, and V/V allele groups, respectively. We did not establish any 
statistically significant differences among the 3 alleles groups in respect to ORR (p=0.93). The OS within 2 years in the F/F, 
V/F, and V/V allele groups was 62.5%, 100%, and 100%, respectively. The OS in the F/F allele group was found to be lower than 
in the other 2 allele groups (p=0.01).
Conclusion: The distribution of gene polymorphisms in our study group was similar to those of previous studies. While oRR 
was similar between the groups, our results highlight a lower OS in F/F patients compared to other allele groups of FcγRIIIA. 
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common 
histological subtype of non-Hodgkin lymphoma (NHL). It 
constitutes 25%-30% of NHLs [1,2]. Cyclophosphamide, 
doxorubicin, vincristine, and prednisone (CHOP) combined 
with rituximab (R) is the standard treatment protocol for 
DLBCL. Before the introduction of rituximab, which is a 
human-mouse chimerical anti-CD20 monoclonal antibody, 
CHOP was used alone. However, it was demonstrated that 
the addition of rituximab to the treatment protocol improves 
the complete remission rate and the 5-year event-free survival 
rate [3]. On the other hand, several studies have shown that 
R-CHOP has some limitations due to tumor pathobiology. 
The biological pathway of rituximab in the treatment of 
lymphomas is still controversial. According to the results of 
in vivo and in vitro studies, researchers have focused on 2 
mechanisms: it increases the efficacy by inducing antibody-
dependent cellular cytotoxicity (ADCC) and complement-
dependent cytotoxicity (CDC) [4,5]. Natural killer (NK) cells, 
macrophages, and neutrophils play major roles in ADCC. 
When they recognize the constant region of the Fcγ receptors 
(FcγR) on the surface of immunoglobulin (Ig), they activate 
in order to initiate the ADCC cascade [6,7]. Macrophages, 
NK cells, and some dendritic cells express FcγRIIIA [8]. There 
may be valine (V) or phenylalanine (F) at the 158th position 
on the FcγRIIIA gene. An in vitro study showed that these 
gene polymorphisms (V/V, F/F, and V/F) change the binding 
affinities to immunoglobulin G (IgG). V/V alleles have the 
strongest affinity to IgG, whereas the F/F alleles have the 
lowest [9]. 
In the current study, we evaluated the distribution of 
FcγRIIIA gene single nucleotide polymorphism (SNP) in 
Turkish patients with DLBCL. The response rate to R-CHOP 
and overall survival (OS), regarding gene polymorphism, 
were also investigated. 
Materials and Methods
Patients’ Characteristics and Treatment Protocol 
Thirty-six newly diagnosed DLBCL patients were 
included. The subjects were recruited from 3 hospitals in 
the Aegean region of Turkey over the course of 30 months. 
Immunohistochemistry staining was performed for all and the 
presence or absence of CD20 was examined. This study was 
approved by the Dokuz Eylül University Faculty of Medicine 
Hospital Ethics Committee and all patients signed an informed 
consent form.
The International Prognostic Index (IPI) score was 
calculated for the prediction of prognosis at the beginning 
of therapy. The chemotherapy regimen was administered 
in 3-week intervals. On the first day, rituximab 375 mg/m2 
was given by intravenous infusion over 4-6 h. On the second 
day, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, 
and vincristine 1.4 mg/m2 (upper limit of 2 mg) were given 
intravenously, while prednisone 100 mg/m2 was administered 
orally on the second day and was then continued for 5 days. 
While stage 1 or 2 disease was generally treated with 4 cycles 
Özet:
Amaç: Diffüz büyük B hücreli non-Hodgkin lenfomada (DLBCL) kür sağlayıcı tedavi yaklaşımı rituximab çağında olmamıza 
rağmen tartışmalı bir konudur. Bu çalışmanın amacı R-CHoP (siklofosfamid, doksorubisin, vinkristin ve prednizon) rejimi alan 
DLBCL hastalarında FcγRIIIA gen polimorfizminin dağılımını incelemekti. Ayrıca FcγRIIIA gen polimorfizminin tüm yanıt oranları 
(oRR) ve tüm yaşam (oS) üzerine olan etkisini araştırmaktı. 
Gereç ve Yöntemler: Türkiye’nin Ege Bölgesi’ndeki üç merkezden yeni tanı almış CD-20 pozitif DLBCL hastaları çalışmaya 
dahil edildi. FcγRIIIA’daki tek gen polimorfizmi gerçek zamanlı-PCR ile incelendi. Tedaviye yanıt, planlanmış olan protokolün 
ortasında ve sonunda değerlendirildi. İki yıllık takip süresince her üç ayda bir hastalığın hem klinik, hem de radyolojik durumu 
ele alındı. 
Bulgular: Çalışmaya dahil edilen 36 hastada, FcγRIIIA’nın F/F, V/F ve V/V alellerinin dağılımı sırasıyla %25, %50 ve %25’ti. oRR 
ve oS verilerine göre 27 hasta değerlendirilebilir olarak kabul edildi. Hastaların oRR değerleri F/F, V/F ve V/V alel gruplarına göre 
sırasıyla %87,5; %100 ve %50 olarak hesaplandı. Hastaların oRR değerleri açısından üç alel grubu arasında istatistiksel olarak 
anlamlı fark saptanmadı (p=0,93). F/F, V/F ve V/V gruplarında iki yıllık oS %62,5, %100 ve %100 bulundu. F/F alel grubunun 
oS’si diğer iki alel grubundakinden daha düşük bulunmuştur (p=0,01). 
Sonuç: Gen polimorfizmi dağılımı sonuçlarımız önceki çalışmalarda bulunanlarla benzerdir. Gruplar arasında oRR değerleri 
arasında fark yokken, sonuçlarımız F/F hastalarının FcγRIIIA’nın diğer allel gruplarına göre daha kısa bir oS değerine sahip 
olduğunu göstermektedir.
Anahtar Sözcükler: FcγRIIIA, Diffüz büyük B hücreli lenfoma, Rituksimab 
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of R-CHOP followed by involved field radiotherapy (RT), the 
advanced stages of disease were treated with 6 to 8 cycles of 
chemotherapy followed by RT if there were bulky tumors. 
In order to assess the response to treatment, patients were 
evaluated after the second or fourth cycles of R-CHOP and 
also after all the planned cycles were completed. Monitoring 
and reevaluations of patients were performed every 3 months. 
All evaluations were performed according to the criteria of the 
International Lymphoma Workshop [10]. Patients fulfilling 
these follow-up criteria were classified as “evaluable”.
FcγRIIIA Gene Polymorphism
Four milliliters of peripheral blood was collected into a 
tube containing EDTA. The genomic DNA was extracted and 
stored at -80 °C. The FcγRIIIA gene V158F polymorphism was 
determined by melting curve analysis after fluorescent real-
time polymerase chain reaction (RT-PCR) on a Light Cycler 
(Roche Diagnostics, Basel, Switzerland). The RT-PCR was 
performed with the FcγRIIIA V158F Toolset for Light Cycler 
containing specific primers and fluorescent oligonucleotide 
probes and the Fast Start DNA Master Hybridization Probe 
Kit (Genes-4U, Neftenbach, Switzerland) according to the 
manufacturer’s instructions. The RT-PCR protocol consisted 
of an initial denaturation step at 95 °C for 2 min, followed by 
40 cycles of 95 °C for 10 s, 56 °C for 10 s, and 72 °C for 10 s. 
The melting protocol consisted of a waiting process at 95 °C 
for 30 s and at 70 °C for 1 min, and a continuous fluorescence 
reading from 70 to 99 °C with a rising rate of 0.1 °C per second.
Statistical Analysis
All available data were analyzed with SPSS 15. We 
performed descriptive analysis for patients’ age, sex, disease 
stage, extranodal involvement, bone marrow infiltration, 
and IPI score according to the FcγRIIIA gene allele groups. 
The variations of the clinical characteristics and treatment 
outcomes of the patients among the gene allele groups were 
compared with Kruskal-Wallis and Mann-Whitney U tests. The 
survival estimates were calculated by Kaplan-Meier technique 
and the differences of OS in gene allele groups were analyzed 
by log-rank test. All the analysis results were interpreted as 
statistically significant if the p-value was smaller than 0.05.
Results
There were 16 males (44.4%) and 20 females (55.6%). 
The median age was 61 (24-82) years at the time of diagnosis. 
The majority of patients (72.2%) had advanced stage disease 
(stages 3 and 4). Extranodal involvement was detected in 
44.4% of the patients and B symptoms were present in 38.9%. 
High-intermediate and high IPI scores were observed in 36.1% 
(n=13) and 27.8% (n=10) of cases, respectively. One-fourth of 
patients had bulky lesions, and bone marrow infiltration was 
seen in 13.9%. The data concerning the patients’ characteristics 
in regard to FcγRIIIA gene alleles is exhibited in Table 1.
The V/F allele was the most frequent type of FcγRIIIA gene 
(50%). The incidences of the remaining alleles were equal 
(25%). We did not find any statistically significant differences 
among gene allele groups in terms of age, sex, B symptoms, 
extranodal involvement, bone marrow infiltration, stage, or 
IPI score (p=0.94, p=0.72, p=0.5, p=0.17, p=0.89, p=0.46, 
p=0.22, respectively). The overall response rate (ORR) to 
R-CHOP was examined in 27 patients. The rest could not 
be reached due to various reasons such as dying before the 
termination of protocol or moving to another city. 
According to our results, there was no statistically 
significant difference in the response rate among the 3 allele 
groups (p=0.93). We performed survival analysis at the end 
of the 30th month. Eight patients in the F/F allele group were 
considered as evaluable. Three of them died within the first 
Büyükkurt N, et al: FcγRIIIA Gene Polymorphism in DLBCL
Table 1. Patients’ characteristics and treatment outcomes 
with R-CHOP (cyclophosphamide, doxorubicin, vincris-
tine, and prednisone) regimen according to FcγRIIIA gene 
alleles.
 F/F V/F V/V
Patients, no. (%) 9 (25) 18 (50) 9 (25)
Sex, no. men/women 4/5 7/11 5/4
Disease, no.    
Stage 3, 4 7 13 6
Extranodal 6 8 2
Bulky 2 5 2
IPI score, no.
Low
Low-intermediate           
 
0
2
 
5
2
 
2
2
High-intermediate 3 7 3
High 4 4 2
Response    
Evaluable 8 15 4
CR 5 14 2
PR 2 1 0
RD 0 0 2
PD 1 0 0
Survival    
Dead 3 0 0
Alive 5 15 4
 
CR: Complete remission, PR: partial remission, RD: refractory disease, PD: pro-
gressive disease.
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year of therapy. One of them had progressive disease after 
R-CHOP and received salvage therapy. Fifteen patients in the 
V/F allele group were evaluable and all were alive. Four of 9 
patients were evaluable in the V/V allele group and none of 
them died during the study interval.
The OS rate within 2 years was 62.5% for the F/F, 100% 
for the V/F, and 100% for the V/V allele group. We found 
statistically significant differences among the V/V-V/F and F/F 
allele groups for OS (p=0.01), as presented in Figure 1.
Discussion
Until the early 2000s, the standard therapy for DLBCL 
was the CHOP combination [11]. Since then, rituximab has 
been added, which was the first monoclonal antibody therapy 
approved by the Food and Drug Administration [12]. While 
significant improvement was achieved with rituximab, its 
mechanism of action is not clearly understood. In vitro and 
in vivo studies highlighted the importance of ADCC, CDC, 
and possibly the activation of the intracellular apoptosis signal 
pathway [4,5]. Recent studies showed that patients with 
follicular lymphoma, Waldenström’s macroglobulinemia, 
and chronic lymphocytic leukemia responded to rituximab 
treatment at different rates due to FcγRIIIA gene SNPs 
[13,14,15,16]. In 2006, Kim et al. stated that the estimated 
benefit of R-CHOP therapy in patients having DLBCL with 
the V/V allele is higher compared to patients with other 
allele types [8]. Ansell et al. demonstrated that rituximab 
improves the response rate not only when combined with 
chemotherapeutic agents, but also when combined with 
cytokines such as interleukin-12. These cytokines play a 
role in cellular cytotoxicity [17]. This report supported the 
idea that rituximab employs its anti-lymphoma effect by 
inducing major mediator cells of the ADCC pathway such as 
macrophages, NK cells, and dendritic cells. In this process, 
rituximab stimulates the effector cells of ADCC, which express 
FcγR after binding to CD20-positive B-cell lymphoma cells. 
FcγRIIIA is one of several types of Fcγ receptors. FcγRIIIA gene 
polymorphisms due to a point mutation at the 158th amino 
acid position may influence the responses of rituximab in 
patients with DLBCL. In their in vitro study, Hatjiharissi et al. 
indicated that individuals with FcγRIIIA V/V and V/F alleles 
showed higher rates of ADCC activity, because the NK cell 
surface has increased expression of FcγRIIIA, which leads to a 
remarkable affinity to rituximab [9]. 
Four previously published reports showed the clinical 
meaning of FcγRIIIA SNPs in DLBCL patients. In the first 
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Figure 1. Overall survival curve of patients in each genotype.
Table 2. Summary of recent papers investigating the clinical importance of FCγRIIIA single nucleotide polymorphism 
(SNPs) in diffuse large B-cell lymphoma (DLBCL) patients.
 
Genotype Distribution ORR (CR+PR) p OS
VV VF FF VV VF FF   
Kim et al. [8], n=113 53 (47%) 54 (48%) 6 (5%) 50 (98%) 48 (90%) 3 (50%) 0.048 82±5* for 2 
years
Váróczy et al. [11], 
n=51
29 
(56.8%)
12 (23.5%) 10 (19.6%) 25 (86%) 10 (83%) 8 (80%) NS 90* for 2 years
Zhang et al. [18], 
n=34
11 (32%) 18 (53%) 5 (15%) 9 (82%) 15 (83%) 3 (60%) 0.04 For 3 years
VV VF FF
58 69 40
Mitroviç et al. [19], 
n=58
16 (28%) 32 (55%) 10 (17%) 12 (75%) 27 (84%) 9 (90%) 0.36 75* for 2 years
ORR: Overall response rate, CR: complete remission, PR: partial remission, OS: overall survival, NS: not significant,
*: total OS value of all types of FCγRIIIA.
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study, Kim et al. found a rapid response to R-CHOP in patients 
with the V/V allele in DLBCL compared to others allele groups 
[8]. The second was published by Zhang et al. They reported 
that V/V and V/F types of FcγRIIIA were evidently more 
responsive to initial R-CHOP therapy, as well as associated 
with longer survival [18]. The last 2 publications were made 
by Váróczy et al. and Mitroviç et al. [11,19]. A summary of 
these recent papers is depicted in Table 2. The results of the 
studies stated above are partially compatible with ours. They 
found no significance between the V/V and F/F alleles in term 
of event-free survival, OS, and ORR in R-CHOP treatment. As 
demonstrated in the last 2 papers, we did not find statistically 
significant differences in ORR, although OS was found 
significantly lower in F/F homozygous patients compared to 
the other 2 allele groups. According to this literature, there are 
2 opposite observations on the same subject. We suppose that 
the reason for such contradicting results may be the different 
actions of the mechanism of rituximab other than the ADCC 
pathway, as well as different tumor pathobiologies. 
Our data have some limitations due to small sample size. 
To our knowledge, there are no other data available about 
this issue for Turkish patients. We suggest that these findings 
be assessed as preliminary data for Turkey. Our results were 
interpreted without drawing a precise conclusion.
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